Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
RANI Rani Therapeutics Holdings Inc
K Kellogg Co
$NQUSM30201030EURT Nasdaq Mid Cap Financial Data Provid
MORF Morphic Holding Inc
STOK Stoke Therapeutics Inc
DUOT Duos Technologies Group Inc
BCLI Brainstorm Cell Therapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
Go

Health Care : Pharmaceuticals | Small Cap Value

Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Closing Price: $1.32

Day's Change: -0.02 (-1.49%)

Bid: --

Ask: --

B/A Size: --

Day's High: 1.33

Day's Low: 1.32

Volume (Heavy Day) Volume: 1,099,211 10-day average volume: 851,265: 1,099,211

There is no peer information for ZYNE.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.